Paramus, N.J.-based the Valley Hospital is the first hospital in the U.S. to use landiolol to treat cardiac arrhythmias in critically ill patients.
Landiolol, approved by the FDA in November 2024, is a fast-acting, intravenous beta blocker that can reduce ventricular rate in adults and children with supraventricular tachycardia. It is often administered in an inpatient hospital setting to critical care patients, according to an April 2 hospital news release.
Currently, the hospital’s cardiac critical care team is administering the medication to treat patients with atrial fibrillation with a rapid heart rate.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
